-
The latest data on allogeneic BCMA CAR-T therapy is positive, and "spot type" cell therapy can be expected in the future. Mai Meng broke the news
Time of Update: 2021-12-30
December 19, 2021/eMedClub News/--At the 63rd Annual Meeting of the American Society of Hematology (ASH) held recently, Allogene Therapeutics focused on the development of allogeneic CAR-T (AlloCAR T™) therapies Announced the positive update results of the Phase 1 study of single-dose ALLO-715 for the treatment of relapsed/refractory (r/r) multiple myeloma .
-
Myeloma. Measurable residual disease in multiple myeloma and light chain amyloidosis: more than just what you see
Time of Update: 2021-12-30
CASSIOPEA trial: Dara-VTd and VTd were compared among 1085 eligible patients for transplantation, and it was found that the MRD-negative rate (NGF, LoD<10-5) of the Dara-VTd group was higher (64% vs.
-
Another company entered the game, CAR-macrophages added help to tumor immunotherapy, Yimai Meng broke the news
Time of Update: 2021-12-30
Founded in 2020, the biotechnology company Inceptor Bio is committed to the development of diverse next-generation cell and gene therapy platforms, including CAR-T, CAR-M, and CAR-NK/NKT, to provide treatments for unmet needs and refractory cancers Method .
-
Ruiqi Orenxel is expected to become the first spot for new treatment options for follicular lymphoma
Time of Update: 2021-12-30
Professor Song Yuqin from Peking University Cancer Hospital, at the 63rd ASH Annual Meeting, orally reported on the relapse and refractory of adult patients after the second-line or above systemic treatment of WuXi Junuo's CAR-T product that targets CD19.
-
2021 ASH master talks about Professor Cai Qingqing: Progress in the treatment of extranodal NK/T cell lymphoma
Time of Update: 2021-12-30
Professor Cai Qingqing from the Cancer Center of Sun Yat-sen University and his team explored the involvement of the central nervous system in patients with extranodal nasal NK/T cell lymphoma, which was selected for this year's ASH poster presentation .
-
Significant progress in JAMA Oncology!
Time of Update: 2021-12-30
Editor’s note iNature is China’s largest academic public account. It is jointly created by a team of doctors from Tsinghua University, Harvard University, Chinese Academy of Sciences and other units
-
Significantly improve the prognosis and survival of patients with advanced liver cancer!
Time of Update: 2021-12-30
544), an authoritative journal in the field of cancer treatment worldwide, published an online publication of a field of interventional therapy for advanced liver cancer by Professor Ming Zhao’s team from the Department of Minimally Invasive Interventional Therapy, Center for Cancer Prevention and Treatment, Sun Yat-sen University Phase III clinical study (FOHAIC-1) .
-
Molecular Cancer Xuzhou Medical University Song Jun/Wang Renhao discovered potential therapeutic targets for colorectal cancer
Time of Update: 2021-12-30
In terms of mechanism, circIL4R is regulated by TFAP2C and competitively interacts with miR-761 to enhance the expression of TRIM29, thereby targeting PHLPP1 for ubiquitin-mediated degradation to activate the PI3K/AKT signaling pathway, thereby promoting the progression of CRC .
-
Lai Suzhiwang's new adjuvant strategy is effective in shrinking tumors and improving prognosis: patients with locally advanced thyroid cancer usher in opportunities for surgery
Time of Update: 2021-12-30
Professor Chen Jiaying said that in these medical reports, we can see that some patients with locally advanced inoperable thyroid cancer After 3-9 months of neoadjuvant therapy with targeted drugs, the patient achieved significant tumor regression and finally successfully underwent surgery .
-
This article sorts out what treatment changes the new generation of ADC drugs bring to HER2-positive breast cancer
Time of Update: 2021-12-30
DS-8201 showed unprecedented activity in the phase II DESTINY-Breast01 clinical trial for patients with advanced HER2-positive breast cancer who had previously received multiple lines of treatment .
-
2021 ASHCNCT19 treatment of children and adults with R/R B-ALL patients 1 year follow-up results
Time of Update: 2021-12-30
The team of Professor Wang Jianxiang from the Hospital of Hematology, Chinese Academy of Medical Sciences explored the safety and efficacy of CNCT19 (a self-targeting CD19 gene-modified T cell immunotherapy) in the treatment of relapsed and refractory (R/R) ALL adults and children.
-
Lasting safety!
Time of Update: 2021-12-30
November 18, 2021/eMedClub News/--Recently, clinical-stage immuno-oncology company CoImmune announced a phase 1/2 clinical trial of an allogeneic CAR-CIK (cytokine-induced killer cell) targeting CD19 The results of the evaluation showed that the drug showed a high degree of safety in children and adult acute lymphoblastic leukemia (ALL) patients after allogeneic hematopoietic stem cell transplantation (HSCT) .
-
"Small size" creates "big value": Domestic trastuzumab helps standardized clinical diagnosis and treatment of breast cancer
Time of Update: 2021-12-30
In this regard, we specially invited Gao Wei, the head nurse of Shandong University Qilu Hospital, to focus on the problem of "surplus fluid management" in the entire management process of breast cancer anti-HER2 treatment .
-
Small specifications and multiple combinations: domestic trastuzumab is ready-to-use, optimizing the overall management of breast cancer patients
Time of Update: 2021-12-30
"Small-size multi-combination" helps the new concept of trastuzumab ready-to-use, reducing the waste of residual fluid while not reducing the efficacy, and bringing patients a better medication experience .
"Small-sized multi-combination" helps the new concept of trastuzumab ready-to-use, and brings patients a better medication experience.
-
"2021 White Paper on the Quality of Life of Lung Cancer Patients in Western China" is officially released, helping doctors and patients to return to a better life
Time of Update: 2021-12-30
Professor Qiu Xiaoming, deputy director of the Lung Cancer Center of West China Hospital of Sichuan University, explained the factors affecting the quality of life of lung cancer patients from the "physical and psychological" aspects of lung cancer patients: "Lung cancer patients not only need to pay attention to physical health, including side effects management and improvement of malnutrition.
-
"Cancer Immunotherapy": Intestine-Liver Axis!
Time of Update: 2021-12-30
Click on the picture to view the details "Intestine·Bacteria Lecture Hall" Provided by the Intestinal Bacteria Alliance Joining the Intestinal Bacteria Alliance Wonderful Review Issue No.
-
2021 Exploration of ASHUblituximab and Umbralisib (U2) in the treatment of chronic lymphocytic leukemia
Time of Update: 2021-12-30
Abstract Number: 395 Title: Ublituximab and Umbralisib (U2) in combination with ibrutinib for the treatment of chronic lymphocytic leukemia (CLL) Phase 2 study: minimal residual disease (MRD)-driven time-limited method researchers explored in ibrutinib The safety and efficacy of U2 therapy in CLL patients whose MRD can be detected after the initial stage of Nimonotherapy .
-
JAMA Sub-Journal: Patients with these diseases, beware of cancer!
Time of Update: 2021-12-30
(Image source: Drug Discovery World) The Harvard University team recently published a study on JAMA Oncology, which confuses the singularity, but the research data is also surprising enough: 470,000 participants from the UK Biobank The data of the authors show that suffering from any kind of "immune-mediated disease" is related to an 8% increase in the risk of cancer .
-
Will the commonly used stomach medicine reduce the treatment effect of lung cancer?
Time of Update: 2021-12-30
The use of proton pump inhibitors and immunotherapy in the treatment of non-small cell lung cancer has significantly reduced the efficacy of atilizumab, but it will not affect the survival of patients who only receive chemotherapy drugs .
-
The Yangtze River Academic Belt Breast Alliance released the top ten "Annual Academic Keywords" for breast cancer in 2021
Time of Update: 2021-12-30
Let’s take a look at the specific analysis of these keywords: TOP 1: CDK4/6 inhibitors (CDK4/6i) This year, at ASCO, ESMO, SABCS and other international academic conferences, the clinical trial results of CDK4/6i were announced, including Overall survival (OS) data from multiple studies .
